Patents Assigned to Bayer Schering Pharma Aktiengesellschaft
-
Publication number: 20140301948Abstract: The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.Type: ApplicationFiled: January 13, 2014Publication date: October 9, 2014Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Ludger DINKELBORG, Matthias FRIEBE, Nikolaevna Raisa KRASIKOWA, Yuri BELOKON, Fedorovna Olga KUZNETSOVA, Keith GRAHAM, Lutz LEHMANN, Mathias BERNDT
-
Publication number: 20140256718Abstract: This invention relates to novel 5-[(hydroxymethyl)aryl]-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders.Type: ApplicationFiled: June 26, 2012Publication date: September 11, 2014Applicants: BAYER INTELLECTUAL PROPERTY GmbH, BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Jürgen Klar, Verena Vöhringer, Joachim Telser, Mario Lobell, Frank Süssmeier, Volkhart Min-Jian Li, Michael Böttger, Stefan Golz, Dieter Lang, Karl-Heinz Schlemmer, Thomas Schlange, Andreas Schall, Wenlang Fu
-
Publication number: 20140227191Abstract: The present invention relates to fluorinated glutamic acid (glutamate) and glutamine derivatives wherein the fluorine atom is 19F. The glutamic acid (glutamate) and glutamine derivatives are compound(s) of general Formula I, which encompasses all possible diastereoisomers and/or enantiomere derivatives or mixtures thereof.Type: ApplicationFiled: April 21, 2014Publication date: August 14, 2014Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Ludger DINKELBORG, Heribert SCHMITT-WILLICH, Keith GRAHAM, Norman KOGLIN, Mathias BERNDT, Matthias FRIEBE, Andre MULLER
-
Publication number: 20130196964Abstract: The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: October 31, 2009Publication date: August 1, 2013Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Michael Härter, Hartmut Beck, Peter Ellinghaus, Kerstin Berhörster, Susanne Greschat, Karl-Heinz Thierauch, Frank Süssmeier
-
Publication number: 20130059844Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.Type: ApplicationFiled: March 26, 2012Publication date: March 7, 2013Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
-
Publication number: 20120282340Abstract: The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-?) selective agonist. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen.Type: ApplicationFiled: November 13, 2009Publication date: November 8, 2012Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Ildiko Terebesi, Adrian Funke, Konstanze Diefenbach, Matthias Schäfers, Sascha General
-
Patent number: 8227598Abstract: The invention relates to novel heteroaryl carboxamides, a process for their preparation, and pharmaceutical compositions containing them. These materials are useful for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.Type: GrantFiled: August 10, 2007Date of Patent: July 24, 2012Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Martin Hendrix, Frank-Gerhard Böβ, Christina Erb, Joachim Krüger, Christoph Methfessel, Rudy Schreiber, Welf-Burkhard Wiese, Joachim Luithle
-
Patent number: 8188270Abstract: The present invention relates to a novel polymorphic form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene-carboxamide, processes for their preparation, medicaments comprising these forms, and their use in the control of diseases.Type: GrantFiled: September 22, 2006Date of Patent: May 29, 2012Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Alfons Grunenberg, Jana Lenz, Gerhard Arnold Braun, Birgit Keil, Christian R. Thomas
-
Patent number: 8158769Abstract: The invention provides isolated nucleic acids molecules, designated hVR-1, hVR-2, and rVR-2 nucleic acid molecules, which encode novel members of the Capsaicin/Vanilloid receptor family. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hVR-1, hVR-2, and rVR-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an hVR-1, hVR-2, and rVR-2 gene has been introduced or disrupted. The invention still further provides isolated hVR-1, hVR-2, and rVR-2 proteins, fusion proteins, antigenic peptides and anti-hVR-1, anti-hVR-2, and anti-rVR-2 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: September 30, 2010Date of Patent: April 17, 2012Assignee: Bayer Schering Pharma AktiengesellschaftInventor: Rory A. J. Curtis
-
Patent number: 8153799Abstract: The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.Type: GrantFiled: August 30, 2010Date of Patent: April 10, 2012Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Timo Flessner, Frank-Gerhard Boss, Christina Erb, Frank-Thorsten Hafner, Katrin Schnizler, Dieter Lang, Joachim Luithle, Marja Van Kampen, Franz-Josef Van Der Staay
-
Patent number: 8143290Abstract: Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.Type: GrantFiled: December 2, 2010Date of Patent: March 27, 2012Assignees: AstraZeneca AB, Bayer Schering Pharma AktiengesellschaftInventors: Markus Berger, Jan Dahmén, Karl Edman, Anders Eriksson, Balint Gabos, Thomas Hansson, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepistö, Darren McKerrecher, Magnus Munck af Rosenschöld, Stinabritt Nilsson, Hartmut Rehwinkel, Camilla Taflin
-
Patent number: 8133689Abstract: The invention provides isolated nucleic acids molecules, designated hVR-1, hVR-2, and rVR-2 nucleic acid molecules, which encode novel members of the Capsaicin/Vanilloid receptor family. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hVR-1, hVR-2, and rVR-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an hVR-1, hVR-2, and rVR-2 gene has been introduced or disrupted. The invention still further provides isolated hVR-1, hVR-2, and rVR-2 proteins, fusion proteins, antigenic peptides and anti-hVR-1, anti-hVR-2, and anti-rVR-2 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: July 6, 2011Date of Patent: March 13, 2012Assignee: Bayer Schering Pharma AktiengesellschaftInventor: Rory A. J. Curtis
-
Publication number: 20120055948Abstract: For safe storage and simple and safe administration of tablets T by a user, a cartridge 900 is provided that can be inserted into a medicament dispenser 1 for solid medicament portions T and that is designed with a reservoir for receiving the medicament portions T, and a medicament dispenser 1 for this cartridge 900 is also provided. According to the invention, the cartridge 900 comprises a singulation device 910 that is designed to dispense defined medicament portions T and that comprises a movable mechanism 940 for separating a defined medicament portion T from the reservoir and for dispensing it from the medicament dispenser 1, wherein the singulation device 910 is designed to produce an operative connection to an actuating device 14, 220, 224, 226; 15, 210; 230 in the medicament dispenser 1.Type: ApplicationFiled: November 14, 2009Publication date: March 8, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Sabine Leifeld, Tom Reinhold, Sven Filler, Uwe Karla, Peter Weber, Nina Voege, Nat Jarvis, Benjamin Holch, James Whittaker
-
Publication number: 20120035409Abstract: This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.Type: ApplicationFiled: February 5, 2010Publication date: February 9, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Martin Michels, Markus Follmann, Alexandros Vakalopoulos, Katja Zimmermann, Mario Lobell, Nicole Teusch, Shendong Yuan
-
Publication number: 20120034272Abstract: The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.Type: ApplicationFiled: November 19, 2009Publication date: February 9, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Alexander Kuhl, Erich Brendel, Frank Bröcker, Adrian Funke, Andreas Ohm, Dennis Kvesic, Thomas Volkmer
-
Publication number: 20120029002Abstract: The present application relates to novel fused, heteroatom-bridged pyrazole and imidazole derivatives, to processes for their preparation, to their use, alone or in combination, for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.Type: ApplicationFiled: January 5, 2010Publication date: February 2, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Alexander Straub, Frank Süßmeier, Frank Wunder, Johannes-Peter Stasch, Volkhart Min-Jian Li, Joachim Mittendorf
-
Publication number: 20120028950Abstract: The present application relates to novel substituted 1-[3-(heterocyclyl)benzyl]-1H-pyrazole derivatives, to processes for preparation thereof, to use thereof for treatment and/or prevention of diseases and to use thereof for production of medicaments for treatment and/or prevention of diseases, more particularly for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: May 9, 2011Publication date: February 2, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Michael HÄRTER, Hartmut BECK, Susanne GRESCHAT, Peter ELLINGHAUS, Kerstin BERHÖRSTER, Joachim SCHUHMACHER
-
Publication number: 20120020881Abstract: This invention relates to novel compounds suitable for labeling by positron emitting isotopes, such as 18F, 11C, 13N and 15O, through appropriate labeling reagents, such as 18F reagents and methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).Type: ApplicationFiled: December 4, 2009Publication date: January 26, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Lutz Lehmann, Timo Stellfeld, Keith Graham, Jessica Becaud, Linjing Mu
-
Patent number: RE43916Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: March 24, 2006Date of Patent: January 8, 2013Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke
-
Patent number: RE44159Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: August 28, 2007Date of Patent: April 16, 2013Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke